Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Collagen Q is a key player for developing rational therapy for congenital myasthenia and for dissecting the mechanisms of anti-MuSK myasthenia gravis.

Ohno K, Ito M, Kawakami Y, Ohtsuka K.

J Mol Neurosci. 2014 Jul;53(3):359-61. doi: 10.1007/s12031-013-0170-x. Review.

PMID:
24234034
2.

Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.

Ohno K, Ito M, Kawakami Y, Krejci E, Engel AG.

Chem Biol Interact. 2013 Mar 25;203(1):335-40. doi: 10.1016/j.cbi.2012.08.020. Epub 2012 Sep 8.

3.

Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Kawakami Y, Ito M, Hirayama M, Sahashi K, Ohkawara B, Masuda A, Nishida H, Mabuchi N, Engel AG, Ohno K.

Neurology. 2011 Nov 15;77(20):1819-26. doi: 10.1212/WNL.0b013e318237f660. Epub 2011 Oct 19.

4.

Mutations in the C-terminal domain of ColQ in endplate acetylcholinesterase deficiency compromise ColQ-MuSK interaction.

Nakata T, Ito M, Azuma Y, Otsuka K, Noguchi Y, Komaki H, Okumura A, Shiraishi K, Masuda A, Natsume J, Kojima S, Ohno K.

Hum Mutat. 2013 Jul;34(7):997-1004. doi: 10.1002/humu.22325. Epub 2013 Apr 19.

PMID:
23553736
5.

[Anti-MuSK antibodies in myasthenia gravis block binding of collagen Q to MuSK].

Ohno K.

Rinsho Shinkeigaku. 2012;52(11):1306-8. Japanese.

PMID:
23196600
6.

Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.

Otsuka K, Ito M, Ohkawara B, Masuda A, Kawakami Y, Sahashi K, Nishida H, Mabuchi N, Takano A, Engel AG, Ohno K.

Sci Rep. 2015 Sep 10;5:13928. doi: 10.1038/srep13928.

7.

Developmental consequences of the ColQ/MuSK interactions.

Karmouch J, Dobbertin A, Sigoillot S, Legay C.

Chem Biol Interact. 2013 Mar 25;203(1):287-91. doi: 10.1016/j.cbi.2012.10.006. Epub 2012 Oct 23. Review.

PMID:
23089045
8.

Roles of collagen Q in MuSK antibody-positive myasthenia gravis.

Ohno K, Otsuka K, Ito M.

Chem Biol Interact. 2016 Nov 25;259(Pt B):266-270. doi: 10.1016/j.cbi.2016.04.019. Epub 2016 Apr 24. Review.

PMID:
27119269
9.

Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction.

Ito M, Suzuki Y, Okada T, Fukudome T, Yoshimura T, Masuda A, Takeda S, Krejci E, Ohno K.

Mol Ther. 2012 Jul;20(7):1384-92. doi: 10.1038/mt.2012.34. Epub 2012 Feb 28.

10.

COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina.

Arredondo J, Lara M, Ng F, Gochez DA, Lee DC, Logia SP, Nguyen J, Maselli RA.

Hum Genet. 2014 May;133(5):599-616. doi: 10.1007/s00439-013-1391-3. Epub 2013 Nov 27.

11.

MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction.

Cartaud A, Strochlic L, Guerra M, Blanchard B, Lambergeon M, Krejci E, Cartaud J, Legay C.

J Cell Biol. 2004 May 24;165(4):505-15.

12.

Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency.

Sigoillot SM, Bourgeois F, Karmouch J, Molgó J, Dobbertin A, Chevalier C, Houlgatte R, Léger J, Legay C.

FASEB J. 2016 Jun;30(6):2382-99. doi: 10.1096/fj.201500162. Epub 2016 Mar 18.

13.

[Congenital myasthenic syndromes].

Ohno K.

Rinsho Shinkeigaku. 2012;52(11):1159-61. Japanese.

PMID:
23196549
14.

Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.

Viegas S, Jacobson L, Waters P, Cossins J, Jacob S, Leite MI, Webster R, Vincent A.

Exp Neurol. 2012 Apr;234(2):506-12. doi: 10.1016/j.expneurol.2012.01.025. Epub 2012 Feb 3.

15.

ColQ controls postsynaptic differentiation at the neuromuscular junction.

Sigoillot SM, Bourgeois F, Lambergeon M, Strochlic L, Legay C.

J Neurosci. 2010 Jan 6;30(1):13-23. doi: 10.1523/JNEUROSCI.4374-09.2010.

16.

Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.

Mori S, Kubo S, Akiyoshi T, Yamada S, Miyazaki T, Hotta H, Desaki J, Kishi M, Konishi T, Nishino Y, Miyazawa A, Maruyama N, Shigemoto K.

Am J Pathol. 2012 Feb;180(2):798-810. doi: 10.1016/j.ajpath.2011.10.031. Epub 2011 Dec 3.

17.

Targeting acetylcholinesterase to the neuromuscular synapse.

Rotundo RL, Rossi SG, Kimbell LM, Ruiz C, Marrero E.

Chem Biol Interact. 2005 Dec 15;157-158:15-21. Epub 2005 Nov 14.

PMID:
16289417
18.

Muscle-specific kinase antibodies: a novel cause of peripheral nerve hyperexcitability?

Simon NG, Reddel SW, Kiernan MC, Layzer R.

Muscle Nerve. 2013 Nov;48(5):819-23. doi: 10.1002/mus.23907. Epub 2013 Jun 26.

PMID:
23720161
19.

Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.

Cole RN, Reddel SW, Gervásio OL, Phillips WD.

Ann Neurol. 2008 Jun;63(6):782-9. doi: 10.1002/ana.21371.

PMID:
18384168
20.

Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis.

Patel V, Oh A, Voit A, Sultatos LG, Babu GJ, Wilson BA, Ho M, McArdle JJ.

PLoS One. 2014 Dec 1;9(12):e110571. doi: 10.1371/journal.pone.0110571. eCollection 2014.

Supplemental Content

Support Center